RSS Feeds
Symptomatic Exacerbation of Crohn Disease after Treatment with High-Dose Interleukin-2
- Joseph A. Sparano, MD;
- Lawrence J. Brandt, MD;
- Janice P. Dutcher, MD;
- Jon S. Dubois, MD; and
- Michael B. Atkins, MD
- From Albert Einstein Cancer Center, Montefiore Medical Center, Bronx, New York; New England Medical Center, Boston, Massachusetts. Requests for Reprints: Joseph A. Sparano, MD, Albert Einstein Cancer Center, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467. Acknowledgments: The authors thank Dr. Panna Mahadevia who assisted in reviewing the pathologic material. Grant Support: In part by a grant from the National Institutes of Health (CA P30CA1130) and an American Cancer Society Career Development Award (JAS, 92-274).
Abstract
Two patients treated with high-dose interleukin-2 (IL-2), who had a history of Crohn disease that was clinically quiescent for 4 and 9 years before therapy, developed symptomatic reactivation of Crohn disease requiring surgical intervention. At laparotomy, both patients had histologic evidence of active Crohn disease. One patient had previously received another cytokine, -interferon-, without disease reactivation, suggesting that this effect was specific for IL-2. The striking temporal relation between the administration of IL-2 and the symptomatic reactivation of previously quiescent Crohn disease suggests the need to carefully evaluate patients with a history of inflammatory bowel disease who are considered for IL-2 therapy and provides evidence supporting an important role for IL-2 in the pathogenesis of Crohn disease.
- Copyright 2004 by the American College of Physicians
